Search Results - "Krishnan, Suba"

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial by Sharma, Padmanee, Prof, Retz, Margitta, Prof, Siefker-Radtke, Arlene, MD, Baron, Ari, MD, Necchi, Andrea, MD, Bedke, Jens, Prof, Plimack, Elizabeth R, MD, Vaena, Daniel, MD, Grimm, Marc-Oliver, Prof, Bracarda, Sergio, MD, Arranz, José Ángel, MD, Pal, Sumanta, MD, Ohyama, Chikara, Prof, Saci, Abdel, PhD, Qu, Xiaotao, PhD, Lambert, Alexandre, PhD, Krishnan, Suba, MD, Azrilevich, Alex, PharmD, Galsky, Matthew D, Prof

“…Summary Background Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to…”
Get full text

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies by Piha‐Paul, Sarina A., Oh, Do‐Youn, Ueno, Makoto, Malka, David, Chung, Hyun Cheol, Nagrial, Adnan, Kelley, Robin K., Ros, Willeke, Italiano, Antoine, Nakagawa, Kazuhiko, Rugo, Hope S., Braud, Filippo, Varga, Andrea Iolanda, Hansen, Aaron, Wang, Hui, Krishnan, Suba, Norwood, Kevin G., Doi, Toshihiko

“…We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE‐158 (NCT02628067; phase 2) and KEYNOTE‐028…”
Get full text

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody by Segal, Neil H, Logan, Theodore F, Hodi, F Stephen, McDermott, David, Melero, Ignacio, Hamid, Omid, Schmidt, Henrik, Robert, Caroline, Chiarion-Sileni, Vanna, Ascierto, Paolo A, Maio, Michele, Urba, Walter J, Gangadhar, Tara C, Suryawanshi, Satyendra, Neely, Jaclyn, Jure-Kunkel, Maria, Krishnan, Suba, Kohrt, Holbrook, Sznol, Mario, Levy, Ronald

“…Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were analyzed to assess safety, tolerability, and…”
Get full text

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies by Chung, Hyun Cheol, Piha-Paul, Sarina A, Lopez-Martin, Jose, Schellens, Jan H M, Kao, Steven, Miller, Jr, Wilson H, Delord, Jean-Pierre, Gao, Bo, Planchard, David, Gottfried, Maya, Zer, Alona, Jalal, Shadia I, Penel, Nicolas, Mehnert, Janice M, Matos, Ignacio, Bennouna, Jaafar, Kim, Dong-Wan, Xu, Lei, Krishnan, Suba, Norwood, Kevin, Ott, Patrick A

“…Pembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028…”
Get more information

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study by Callahan, Margaret K, Kluger, Harriet, Postow, Michael A, Segal, Neil H, Lesokhin, Alexander, Atkins, Michael B, Kirkwood, John M, Krishnan, Suba, Bhore, Rafia, Horak, Christine, Wolchok, Jedd D, Sznol, Mario

“…Purpose The clinical activity observed in a phase I dose-escalation study of concurrent therapy with nivolumab (NIVO) and ipilimumab (IPI) in patients with…”
Get full text

Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial by Reardon, David A., Kim, Tae Min, Frenel, Jean‐Sebastien, Simonelli, Matteo, Lopez, Juanita, Subramaniam, Deepa S., Siu, Lillian L., Wang, Hui, Krishnan, Suba, Stein, Karen, Massard, Christophe

“…Background Current treatments for recurrent glioblastoma offer limited benefit. The authors report the antitumor activity and safety of the anti–programmed…”
Get full text

Safety and efficacy of etigilimab in combination with nivolumab in select recurrent/advanced solid tumors by McKean, Meredith, Dumbrava, Ecaterina Elena, Hamid, Omid, Merriam, Priscilla, Mettu, Niharika B., Call, Justin A, Kapoun, Ann M., Lucas, Jennifer, Seetharam, Mahesh, Vaishampayan, Ulka N., Weroha, Saravut John, Krishnan, Suba, George, Angela Joy

“…2651 Background: Etigilimab (etig), a humanized IgG1 monoclonal antibody, blocks TIGIT interaction with PVR (poliovirus receptor) and inhibits downstream…”
Get full text

Increased levels of the inflammatory biomarker C‐reactive protein at baseline are associated with childhood sickle cell vasocclusive crises by Krishnan, Suba, Setty, Yamaja, Betal, Suhita G., Vijender, Vaidyula, Rao, Koneti, Dampier, Carlton, Stuart, Marie

“…Summary Several lines of evidence suggest that sickle cell disease (SCD) is associated with a chronic inflammatory state. In this study of 70 children with SCD…”
Get full text

Abstract CT229: Olaparib in patients (pts) with previously treated, homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD)-positive advanced cancer: Phase II LYNK-002 study by Hyman, David, Hendifar, Andrew, Chung, Hyun Cheol, Maio, Michele, Leary, Alexandra, Spanggaard, Iben, Rhee, Joon, Marton, Matt, Chen, Menghui, Krishnan, Suba, Shapira, Ronnie

“…Abstract Background: Human cancers are associated with defects in DNA damage repair (DDR). Evidence suggests a key role for poly(ADP-ribose) polymerases…”
Get full text

Abstract CT073: Pembrolizumab after two or more lines of prior therapy in patients with advanced small-cell lung cancer (SCLC): Results from the KEYNOTE-028 and KEYNOTE-158 studies by Chung, Hyun Cheol, Piha-Paul, Sarina A., Lopez-Martin, Jose, Schellens, Jan H.M., Kao, Steven, Miller, Wilson H., Delord, Jean-Pierre, Gao, Bo, Planchard, David, Gottfried, Maya, Zer, Alona, Jalal, Shadia I., Penel, Nicolas, Mehnert, Janice M., Matos, Ignacio, Bennouna, Jaafar, Kim, Dong-Wan, Xu, Lei, Krishnan, Suba, Norwood, Kevin, Ott, Patrick A.

“…Abstract Background: The antitumor activity of the anti-PD-1 monoclonal antibody pembrolizumab in patients with advanced SCLC has been evaluated in the Phase…”
Get full text

Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies by Bang, Yung-Jue, Ueno, Makoto, Malka, David, Chung, Hyun Cheol, Nagrial, Adnan, Kelley, Robin Kate, Piha-Paul, Sarina Anne, Ros, Willeke, Italiano, Antoine, Nakagawa, Kazuhiko, Rugo, Hope S., De Braud, Filippo G., Varga, Andrea I., Hansen, Aaron Richard, Gao, Chao, Krishnan, Suba, Norwood, Kevin, Doi, Toshihiko

“…Abstract only 4079 Background: Antitumor activity with pembro, an anti–PD-1 antibody, has been observed in patients (pts) with advanced/metastatic biliary…”
Get full text

Tissue factor-positive monocytes in children with sickle cell disease: correlation with biomarkers of haemolysis by Setty, B. N. Yamaja, Key, Nigel S., Rao, A. Koneti, Gayen-Betal, Suhita, Krishnan, Suba, Dampier, Carlton D., Stuart, Marie J.

“…Summary Tissue Factor (TF) initiates thrombin generation, and whole blood TF (WBTF) is elevated in sickle cell disease (SCD). We sought to identify the…”
Get full text

Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease by Quinn, Charles T., Stuart, Marie J., Kesler, Karen, Ataga, Kenneth I., Wang, Winfred C., Styles, Lori, Smith‐Whitley, Kim, Wun, Ted, Raj, Ashok, Hsu, Lewis L., Krishnan, Suba, Kuypers, Frans A., Setty, Yamaja, Rhee, Seungshin, Key, Nigel S., Buchanan, George R.

“…Summary Tapered oral dexamethasone for acute chest syndrome (ACS) in sickle cell anaemia was studied using a novel ACS assessment tool and investigational…”
Get full text

Increased von Willebrand factor antigen and high molecular weight multimers in sickle cell disease associated with nocturnal hypoxemia by Krishnan, Suba, Siegel, Jamie, Pullen, Gene, Hevelow, Megan, Dampier, Carlton, Stuart, Marie

“…Abstract We evaluated vWF profiles in children and adolescents with SCD and sleep hypoxemia. Mean vWF:Ag levels were significantly elevated in the…”
Get full text

Tissue Factor Procoagulant Activity and Coagulation Activation In Sickle Cell Disease: Relationship with Biomarkers of Hemolysis and Inflammation by Setty, Yamaja, Key, Nigel S., Rao, Angara Koneti, Krishnan, Suba, Gayen-Betal, Suhita, Stuart, Marie J

“…Abstract 4210 Several lines of evidence suggest that hemostasis is activated in patients with chronic hemolytic anemias, including sickle cell disease (SCD),…”
Get full text

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) by Sznol, Mario, Kluger, Harriet M., Callahan, Margaret K., Postow, Michael Andrew, Gordon, Ruth Ann, Segal, Neil Howard, Rizvi, Naiyer A., Lesokhin, Alexander M., Atkins, Michael B., Kirkwood, John M., Burke, Matthew M., Ralabate, Amanda L., Rivera, Angel L., Kronenberg, Stephanie Anne, Agunwamba, Blessing, Feely, William, Hong, Quan, Krishnan, Suba, Gupta, Ashok Kumar, Wolchok, Jedd D.

“…Abstract only LBA9003^ Background: We report updated survival and clinical activity in initially enrolled cohorts and activity by BRAF MT status in a phase I…”
Get full text

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) by Sznol, Mario, Kluger, Harriet M., Callahan, Margaret K., Postow, Michael Andrew, Gordon, Ruth Ann, Segal, Neil Howard, Rizvi, Naiyer A., Lesokhin, Alexander M., Atkins, Michael B., Kirkwood, John M., Burke, Matthew M., Ralabate, Amanda L., Rivera, Angel L., Kronenberg, Stephanie Anne, Agunwamba, Blessing, Feely, William, Hong, Quan, Krishnan, Suba, Gupta, Ashok Kumar, Wolchok, Jedd D.

“…Abstract only…”
Get full text

Imbalance in Arachidonic Acid to Docosahexaenoic Acid Ratios in the Sickle Red Cell Is Associated with Inflammation by Setty, Yamaja, Gayen-Betal, Suhita, Krishnan, Suba, Meier, Maureen, Cahill, Michele, Stuart, Marie J.

“…Abstract 2566 Poster Board II-543 The polyunsaturated fatty acids (PUFAs): arachidonic acid (AA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA)…”
Get full text

Is determination of creatine kinase-2 after electrophoretic separation accurate? by Henderson, A R, Stark, J A, McQueen, M J, Patten, R L, Krishnan, S, Wood, D E, Webb, S

“…Since 1991, the Ontario Laboratory Proficiency Testing Program has assessed the analytical performance of creatine kinase (CK; EC 2.7.3.2) isoenzyme-2, using…”
Get more information

Annexin II: A Mediator of the Plasmin /Plasminogen Activator System by Hajjar, Katherine A, Krishnan, Suba

“…The annexins constitute a family of calcium-dependent membrane binding proteins. Recently, annexin II has been shown to accelerate the activation of the…”
Get full text